1-(2-(4-(4-methoxyphenyl)-1,2,3-triazol-1-yl)ethyl)piperidine | 1246847-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2-(4-(4-methoxyphenyl)-1,2,3-triazol-1-yl)ethyl)piperidine
• 英文别名: 1-[2-[4-(4-Methoxyphenyl)triazol-1-yl]ethyl]piperidine
• CAS: 1246847-72-2
• 化学式: C₁₆H₂₂N₄O
• 分子量: 286.377
• InChiKey: KUHDJJMREQPDIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2-氨乙基)哌啶 在 copper(ll) sulfate pentahydrate 、 triflic azide 、 potassium carbonate 、 sodium ascorbate 作用下， 以 乙醇 、 水 、 甲苯 、 叔丁醇 为溶剂， 生成 1-(2-(4-(4-methoxyphenyl)-1,2,3-triazol-1-yl)ethyl)piperidine
  参考文献：
  名称：

  Selectivity Optimization of Substituted 1,2,3-Triazoles as α7 Nicotinic Acetylcholine Receptor Agonists

  摘要：

  Three series of substituted anti-1,2,3-triazoles (IND, PPRD, and QND), synthesized by cycloaddition from azide and alkyne building blocks, were designed to enhance selectivity and potency profiles of a lead alpha 7 nicotinic acetylcholine receptor (alpha 7-nAChR) agonist, TTIn-1. Designed compounds were synthesized and screened for affinity by a radioligand binding assay. Their functional characterization as agonists and antagonists was performed by fluorescence resonance energy transfer assay using cell lines expressing transfected cDNAs, alpha 7-nAChRs, alpha 4 beta 2-nAChRs, and 5HT(3A), receptors, and a fluorescence cell reporter. In the END series, a tropane ring of TTIn-1, substituted at Ni, was replaced by mono- and bicyclic amines to vary length and conformational flexibility of a carbon linker between nitrogen atom and Ni of the triazole. Compounds with a two-carbon atom linker optimized binding with K-d's at the submicromolar level. Further modification at the hydrophobic indole of TTIn-1 was made in PPRD and QND series by fixing the amine center with the highest affinity building blocks in the IND series. Compounds from IND and PPRD series are selective as agonists for the alpha 7-nAChRs over alpha 4 beta 2-nAChRs and 5HT(3A) receptors. Lead compounds in the three series have EC50's between 28 and 260 nM. Based on the EC50, affinity, and selectivity determined from the binding and cellular responses, two of the leads have been advanced to behavioral studies described in the companion article (DOI: 10.1021/acschemneuro.5b00059).

  DOI：

  10.1021/acschemneuro.5b00058

文献信息

• Chelation-Assisted, Copper(II)-Acetate-Accelerated Azide−Alkyne Cycloaddition
  作者：Gui-Chao Kuang、Heather A. Michaels、J. Tyler Simmons、Ronald J. Clark、Lei Zhu

  DOI：10.1021/jo101305m

  日期：2010.10.1

  complex of T6 were characterized by X-ray crystallography. The structure of [Cu(T1)2(H2O)2](ClO4)2 reveals the interesting synergistic effect of hydrogen bonding, π−π stacking interactions, and metal coordination in forming a one-dimensional supramolecular construct in the solid state. The tetradentate coordination mode of T6 may be incorporated into designs of new molecule sensors and organometallic

  我们在之前的通讯中描述了流行的 Cu I催化的叠氮化物-炔烃环加成 (AAC) 过程的变体，其中 5 mol% 的 Cu(OAc) 2在不添加任何还原剂的情况下足以进行反应。发现 2-吡啶甲酰叠氮化物( 1 ) 和 2-叠氮甲基喹啉 ( 2 ) 是迄今为止最具反应性的叠氮化碳底物，在所发现的条件下，它们可在短短几分钟内转化为 1,2,3-三唑。我们假设1和2螯合 Cu II 的能力对观察到的高反应速率有显着贡献。目前的工作检查了在 Cu II 的吡啶基以外的叠氮基附近的辅助配体对 Cu(OAc) 2加速的 AAC 反应效率的影响。在报道的条件下，能够以螯合方式与烷基化叠氮氮的催化铜中心结合的碳叠氮化物确实被证明是优良的底物。在 X 射线单晶结构中证明了叠氮化碳11和 Cu II之间的螯合。在一组有限的例子中，由 Fokin 等人开发的配体三（苄基三唑基甲基）胺（TBTA）。用于辅助原始 Cu
• SELECTIVE ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20180244653A1

  公开（公告）日：2018-08-30

  In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype based on receptor occupation and response, behavioral assessments for reversing cognitive impairment after scopolamine treatment, enhancing memory retention over time, pharmaceutical compositions and formulations and devices comprising them, and methods for making and using them, including characterizing and efficiently assaying them for receptor subtype selectivity. In alternative embodiments, provided are substituted anti 1,2,3-triazoles compounds with high affinity, and selective binding, for the alpha7 nicotine acetylcholine receptor (α7 nAChR), as exemplified by 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND1”), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND8”) and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine (“QND8”). In alternative embodiments, provided are products of manufacture such as pumps, devices, syringes and the like comprising a compound, pharmaceutical composition or formulation as provided herein.

  在另一种实施方式中，提供了对α7尼古丁乙酰胆碱受体（α7 nAChR）具有高亲和力的选择性激动剂，基于受体占据和响应的选择性尼古丁受体亚型和配体门控离子通道亚型的筛选方法，行为评估用于在施用东莨菪碱后逆转认知障碍，随时间增强记忆保留，包括表征和高效筛选受体亚型选择性的制备和使用方法的制药组合物和配方以及包括它们的装置，提供了具有高亲和力和选择性结合的替代抗1,2,3-三唑化合物，例如5-（1-（2-（哌啶-1-基）乙基）-1H-1,2,3-三唑-4-基）-1H-吲哚（“IND1”），5-（（喹啉-3-基）-1H-1,2,3-三唑-4-基）-1H-吲哚（“IND8”）和3-（4-羟基苯基-1,2,3-三唑-1-基）喹啉（“QND8”）。在另一种实施方式中，提供了制造产品，例如泵、装置、注射器等，其中包括本文提供的化合物、制药组合物或配方。
• Selective alpha-7 nicotinic receptor agonists and methods for making and using them
  申请人：The Regents of the University of California

  公开号：US10308638B2

  公开（公告）日：2019-06-04

  In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype based on receptor occupation and response, behavioral assessments for reversing cognitive impairment after scopolamine treatment, enhancing memory retention over time, pharmaceutical compositions and formulations and devices comprising them, and methods for making and using them, including characterizing and efficiently assaying them for receptor subtype selectivity. In alternative embodiments, provided are substituted anti 1,2,3-triazoles compounds with high affinity, and selective binding, for the alpha7 nicotine acetylcholine receptor (α7 nAChR), as exemplified by 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND1”), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND8”) and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine (“QND8”). In alternative embodiments, provided are products of manufacture such as pumps, devices, syringes and the like comprising a compound, pharmaceutical composition or formulation as provided herein.

  在另一个实施方案中，提供了对α7烟碱乙酰胆碱受体（α7 nAChR）具有高亲和力的选择性激动剂、基于受体占据和反应的烟碱受体亚型和配体门控离子通道亚型选择性的检测方法、在东莨菪碱治疗后逆转认知障碍的行为评估、随时间增强记忆保持、药物组合物和制剂及包含它们的装置，以及制造和使用它们的方法，包括表征和有效测定它们的受体亚型选择性。在另一种实施方案中，提供了对α7 尼古丁乙酰胆碱受体（α7 nAChR）具有高亲和力和选择性结合的取代抗 1,2,3-三唑化合物、例如 5-(1-(2-(哌啶-1-基)乙基)-1H-1,2,3-三唑-4-基)-1H-吲哚（"IND1"）、5-((奎宁环-3-基)-1H-1,2,3-三唑-4-基)-1H-吲哚（"IND8"）和 3-(4-羟基苯基-1,2,3-三唑-1-基)奎宁环（"QND8"）。在另一种实施方案中，提供了包含本文所提供的化合物、药物组合物或制剂的制造产品，如泵、装置、注射器等。
• [EN] SELECTIVE ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM<br/>[FR] AGONISTES SÉLECTIFS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2016154434A1

  公开（公告）日：2016-09-29

  In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype based on receptor occupation and response, behavioral assessments for reversing cognitive impairment after scopolamine treatment, enhancing memory retention over time, pharmaceutical compositions and formulations and devices comprising them, and methods for making and using them, including characterizing and efficiently assaying them for receptor subtype selectivity. In alternative embodiments, provided are substituted anti 1,2,3-triazoles compounds with high affinity, and selective binding, for the alpha7 nicotine acetylcholine receptor (α7 nAChR), as exemplified by 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole ("IND1"), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole ("IND8") and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine ("QND8"). In alternative embodiments, provided are products of manufacture such as pumps, devices, syringes and the like comprising a compound, pharmaceutical composition or formulation as provided herein.